# VACCINE/PROPHYLACTIC TRIAL SUMMARY

---

### University of Oxford & AstraZeneca - (AZD1222; ChAdOx1 nCoV-19)

- [Preclinical Results](https://www.nature.com/articles/d41586-020-01092-3)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04324606) - 1090 subjects - Started April 23 2020 [Results](<https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext>)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04444674) - 2,000 subjects - Started June 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04568031) - 12 subjects (Japan) - Started August 23 2020
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04400838) - 12,330 subjects (UK) - Started May 28 2020
- [Phase 3](http://www.isrctn.com/ISRCTN89951424) - 5,000 subjects (Brazil) - Started June 28 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04444674) - 2,000 subjects (South Africa) - Started July 1 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04516746) - 30,000 subjects (US) - Started August 17 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04540393) - 100 subjects (Russia) - Status unknown

---

### Sinovac - (CoronaVac)

- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04352608) - 744 subjects (144 Phase 1 / 600 Phase 2) - Started April 16 2020 - [Interim Results](https://www.statnews.com/2020/06/14/sinovac-early-data-covid19-vaccine-generated-immune-responses/)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04383574) - 422 subjects - Starting May 20 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04551547) - 552 subjects - Started September?
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04456595) - 8,870 subjects (healthcare professionals; Brazil) - Started July 21 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04508075) - 1,620 subjects (Indonesia) - Started August 10 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04582344) - 13,000 subjects (Turkey) - Started September 14 2020

---

### Sinopharm & Wuhan Institute of Biological Products - (Inactivated Vaccine)

- [Phase 1/2](https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving) - 1,120 subjects - Started April 12 2020 - [Results](https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving)
- [Phase 3](https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving) - 15,000 subjects - maybe up to [31,000](https://www.reuters.com/article/health-coronavirus-emirates-vaccine-int/uae-company-nears-end-of-chinese-covid-19-vaccine-trial-idUSKBN26T1N5) (United Arab Emirates; Bahrain; Egypt, Jordan) - Started July 15 2020 Finished [August 13th 2020](https://www.fiercepharma.com/vaccines/china-sinopharm-chief-narrows-down-covid-19-vaccine-price-to-within-145-for-2-dose-regimen)

---

### Moderna Therapeutics - (mRNA-1273)

- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04283461) - 155 subjects - Started March 16 2020 - [Interim Results](https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04405076) - 600 subjects (US) - Started May 29, 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04470427?term=NCT04470427) - 30,000 subjects (US) - Starts July 27 2020

---

### BioNTech & Pfizer - (BNT162)

- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04523571) - 144 subjects - Started September 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04380701) - 456 subjects - Starting November 2020 - [Interim Results](https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1) [Results](https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1)
- [Phase 2/3](https://clinicaltrials.gov/ct2/show/NCT04368728) - 43,998 subjects (US) - Started April 29, 2020 - [Interim Results](https://investors.pfizer.com/investor-news/press-release-details/2020/Pfizer-and-BioNTech-Announce-Vaccine-Candidate-Against-COVID-19-Achieved-Success-in-First-Interim-Analysis-from-Phase-3-Study/default.aspx)

---

### Johnson & Johnson / Janssen - (Ad26.COV2-S)

- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04509947) - 250 subjects - Started August 11 2020
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04436276) - 1,045 subjects - Started July 15, 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04505722) - 60,000 subjects - Starting September 5 2020

---

### CanSino Biologics - (Ad5-nCoV)

- [Phase 1](https://www.clinicaltrials.gov/ct2/show/NCT04313127) - 108 subjects - started March 16 2020 - [Results](<https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31208-3.pdf>)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04398147) - 696 subjects (Canada) - Status Uncertain
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04341389) - 508 subjects - Started April 12 2020 - [Results](<https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext>)
- [Phase 2](https://www.clinicaltrials.gov/ct2/show/NCT04566770) - 481 subjects (China) - Started September 24, 2020
- [Phase 3](https://www.clinicaltrialsarena.com/news/cansino-vaccine-saudi-trial/) - 5,000 subjects (Saudi Arabia) - Status Uncertain
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04540419) - 500 subjects (Russia) - Started September 11, 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04526990) - 40,000 subjects (Pakistan) - Started September 15, 2020

---

### Novavax - (NVXâ€‘CoV2373)

- [Preclinical Results](https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1)
- [Phase 1/2](https://www.clinicaltrials.gov/ct2/show/NCT04368988) - 1,419 subjects (US, Australia) - Started May 25 2020 - [Results](https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1)
- [Phase 2b](https://clinicaltrials.gov/ct2/show/NCT04533399) - 4,400 subjects (South Africa) - Started August 17, 2020
- [Phase 3](https://www.clinicaltrials.gov/ct2/show/NCT04583995) - 9,000 subjects (UK) - started September 28, 2020
  Phase 3 - 30,000 subjects - Starting Late November

---

### Inovio - (INO-4800)

- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04336410) - 120 subjects (US) - Started April 3 2020 - [Interim Results](https://www.statnews.com/2020/06/30/inovio-claims-positive-results-on-covid-19-vaccine-but-critical-data-are-missing/)
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04447781) - 160 subjects (US) - Started July 15 2020
  Phase 2/3 - On Partial Clinical Hold

---

### Anhui Zhifei - (Recombinant Coronavirus Vaccine)

- [Phase 1](https://clinicaltrials.gov/ct2/show/NCT04445194) - 50 subjects (China) - Started June 22 2020
- [Phase 2](https://clinicaltrials.gov/ct2/show/NCT04466085) - 900 subjects (China) - Started July 12 2020
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04550351) - 50 subjects (China) - Started August 19, 2020

---

### Sinopharm & Beijing Institute of Biological Products - (Inactivated Vaccine)

- [Preclinical Results](<https://www.cell.com/cell/pdf/S0092-8674(20)30695-4.pdf>)
- [Phase 1/2](http://www.chictr.org.cn/showproj.aspx?proj=53003) - 2048 subjects (China) - Started April 28 2020

---

### Chinese Academy of Medical Sciences - (Inactivated SARS-CoV-2 Vaccine)

- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04412538) - 942 subjects (China) - Started May 15 2020
- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04470609) - 471 subjects (China) - Started July 10 2020

---

### Genexine - (GX-19)

- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04445389) - 190 subjects (South Korea) - Started June 17 2020

---

### Gamaleya Research Institute - (Gam-COVID-Vac)

- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04436471) - 38 Subjects (Russia) - Started June 17 2020

---

### Imperial College London - (LNP-nCoVsaRNA)

- [Phase 1/2](http://www.isrctn.com/ISRCTN17072692) - 300 subjects (UK) - Started Jun 23 2020

---

### Bharat Biotech - (BBV152)

- [Phase 1/2](http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45184&EncHid=&userName=bbv152) - 1,125 subjects (India) - Started July 13 2020 - [P1 Results](https://www.clinicaltrialsarena.com/news/bharat-biotech-covaxin-data/)

---

### Zydus Cadilla - (DNA plasmid Vaccine)

- [Phase 1/2](http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&EncHid=&userName=vaccine) - 1,048 subjects (India) - Started July 15 2020

---

### Kentucky BioProcessing - (KBP-COVID-19)

- [Phase 1/2](https://clinicaltrials.gov/ct2/show/NCT04473690?) - 180 subjects - Starting July 20 2020

---

### Instituto Finlay de Vacunas - (Soberana 1)

- [Phase 1/2](https://rpcec.sld.cu/ensayos/RPCEC00000332-Sp) - Starting September?

---

### Regeneron - REGN-COV2 (monoclonal antibody)

- [Phase 1/2/3](https://clinicaltrials.gov/ct2/show/NCT04425629) (Treatment) - 1,054 subjects - Started Jun 16 2020
- [Phase 3](https://clinicaltrials.gov/ct2/show/NCT04452318) (Prevention) - 2,000 subjects - Starting July

---

#### Note: Includes vaccines and monoclonal antibodies that have reached Phase 2 or Phase 3. Trial Registry links and publication linked provided if available, otherwise news articles linked.

## Other Sources of Information:

- [STAT News](https://www.statnews.com/feature/coronavirus/drugs-vaccines-tracker/?utm_campaign=cv_landing#vaccines)
- [Clinical Trials Arena](https://www.clinicaltrialsarena.com/tag/coronavirus/)
- [TrialSiteNews](https://www.trialsitenews.com/the-covid-19-vaccine-race-status-update-as-of-july-5-2020/)
- [Milken Tracker](https://covid-19tracker.milkeninstitute.org/#vaccines_intro)
- [NYT Vaccine Tracker](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)
- [WHO Draft Landscape](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
- [RA Capital Tracker](https://www.racap.com/covid-19)
- [BioWorld Tracker](https://www.bioworld.com/COVID19products)
- [Coronavirus Today](https://www.coronavirustoday.com/coronavirus-vaccines-0)
